Skip to main content
Premium Trial:

Request an Annual Quote

FDA Expands Approval of Roche Cobas Test as CDx for EGFR Deletions, Mutations

NEW YORK (GenomeWeb) – Roche said today that the US Food and Drug Administration has granted premarket approval for expanded use of its Cobas EGFR Mutation Test v2 as a companion diagnostic test with AstraZeneca's Tagrisso (osimertinib) for non-small cell lung cancer patients.

The agency has approved the CDx for first-line treatment of patients diagnosed with metastatic NSCLC whose tumors have epidermal growth factor receptor exon 19 deletions or exon 21 L858R mutations. It had previously approved the test as a CDx with Tagrisso for second-line treatment and beyond in NSCLC patients who test positive for the EGFR T790M mutation.

The test is also approved as a CDx with Tarceva (erlotinib) for NSCLC patients who test positive for the EGFR exon 19 deletion or L858R sensitizing mutations.

Approvals thus far cover tissue and blood plasma patient biopsies, Roche said.

EGFR testing in plasma offers a non-invasive option for patients using a blood draw for those who are not eligible for a tissue biopsy, and the Cobas test workflow enables patients and clinicians to obtain results in one day, the firm said.

That provides the information needed "to choose the optimal therapy and avoid delays in getting…patients started on treatment," Sid Scudder, senior director of clinical research, genomics, and oncology at Roche Molecular Diagnostics, said in a statement.

Roche said clinical studies have demonstrated that patients benefit from tyrosine kinase inhibitor therapies after they have been diagnosed with NSCLC and have tested positive for defined mutations of the EGFR gene.


The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.